For example, GLS inhibition with CB-839 negatively impacted immune activation by the anti-PD1 immunotherapy in the transgenic murine models of KRAS/Serine-threonine kinase 11 (STK11)-mutant lung adenocarcinoma carrying an immune suppressive mutation in the STK11 gene. This evidence concerns the gene STK11 and lung adenocarcinoma.